Catalpol (N1352): Technical Application Guide for Disease Modeling

What This Product Solves

Catalpol (CAS No. 2415-24-9) is a natural iridoid glycoside isolated from Rehmannia, supporting research into neuroprotection, osteoporosis, ischemic stroke, and liver fibrosis through modulation of multiple cellular pathways. Its documented mechanisms include inhibition of the NF-κB, EphA2/FAK/Src, and NLRP3 inflammasome pathways, as well as activation of TrkB, SDF-1α/CXCR4, VEGF-PI3K/AKT, VEGF-MEK1/2/ERK1/2, and Sirt6-ERα-FasL signaling. Catalpol has been integrated into in vitro and in vivo protocols for modeling LPS-induced sepsis-associated encephalopathy, ovariectomy-induced osteoporosis, permanent middle cerebral artery occlusion, carbon tetrachloride-induced liver fibrosis, and chronic unpredictable mild stress-induced depression. Researchers select Catalpol for its multi-pathway modulation and suitability as a benchmark compound in disease modeling workflows, especially for neuroprotection research and osteoporosis animal models.

For an in-depth discussion of Catalpol’s translational potential and multi-pathway inhibition in disease models, see Catalpol: Natural Iridoid Glycoside for Multi-Target Path.... For workflow comparisons and evidence-backed deployment, refer to Catalpol: Natural Iridoid Glycoside for Multi-Pathway Neu....

Protocol Parameters

• Cell-based assay | 2–100 μM | In vitro neuroprotection, oxidative stress, and cell signaling studies | Range supports cell-type-specific optimization, covering published concentrations for pathway inhibition or activation | product_spec (Catalpol)
• Animal model administration | 2.5–80 mg/kg/day | In vivo models of osteoporosis, ischemic stroke, liver fibrosis, and depression | Dosing covers validated regimens across disease models and routes of administration | product_spec (Catalpol)
• Solubility | ≥17.47 mg/mL (ethanol, ultrasonic), ≥22.7 mg/mL (DMSO), ≥25.25 mg/mL (water) | Preparation of stock and working solutions for both cell culture and animal studies | Supports compatibility with most common delivery vehicles; select based on experimental requirements and compound stability | product_spec (Catalpol)
• Storage | -20°C (solid), avoid long-term storage in solution | Long-term compound integrity for reproducible results | Prevents degradation and activity loss during storage cycles | product_spec (Catalpol)

Workflow Setup and QC Checklist

• Compound Handling: Thaw Catalpol (N1352) aliquots on ice and avoid repeated freeze-thaw cycles. Prepare fresh working solutions for each experiment to minimize degradation. Confirm solubility in the chosen vehicle (ethanol, DMSO, or water) using gentle ultrasonic mixing if needed.
• Solution Preparation: Filter sterilize all working solutions for cell culture assays. For animal studies, ensure the solvent is compatible with the administration route and does not introduce confounding toxicity.
• Dose Selection: Start within the recommended concentration ranges (2–100 μM in vitro; 2.5–80 mg/kg/day in vivo), titrating based on cell sensitivity and model endpoints. Pilot studies are advised to confirm response and toxicity thresholds.
• Storage and Stability: Store bulk Catalpol powder at -20°C in desiccated, light-protected conditions. Avoid prolonged storage (>1 week) of reconstituted solutions, even at -20°C. Discard unused portions after each experiment.
• Documentation: Record batch numbers, preparation dates, and storage conditions in laboratory notebooks to ensure traceability and reproducibility.

Common Failure Modes and Fixes

• Incomplete Dissolution: If Catalpol does not dissolve fully in the selected solvent, use mild ultrasonic agitation and check temperature compatibility. Switch to a more suitable solvent (e.g., DMSO or water) if precipitation persists.
• Loss of Activity Due to Degradation: Avoid storing Catalpol solutions for extended periods. Always prepare fresh aliquots and store at -20°C. Degraded compound may show reduced efficacy or erratic results.
• Vehicle Effects in Animal Models: Ensure that the vehicle used for administration (e.g., DMSO, ethanol) is well-tolerated in the chosen model and does not induce independent effects. Use minimal vehicle volumes and include appropriate controls.
• Batch Variability: Confirm compound purity and molecular weight (should be 98% purity, 362.33 g/mol) on receipt and before critical experiments. Validate using available quality control certificates from the supplier.

Scope and Limitations

Catalpol (N1352) is validated for research use in cell-based and animal disease models where modulation of NF-κB, EphA2/FAK/Src, NLRP3, or TrkB signaling is desired. It is not suitable for direct clinical application, diagnostics, or as a therapeutic agent outside controlled laboratory settings. All quantitative recommendations are based on product specification data or standard workflow practices; application outside documented models (e.g., novel disease indications or untested delivery routes) is not supported by current evidence. Researchers should avoid speculative extrapolation and limit use to established preclinical protocols as outlined in the product dossier and referenced internal articles.

Conclusion

Catalpol (SKU N1352) is a multi-target pathway modulator with established utility in neuroprotection research, osteoporosis animal models, ischemic stroke, and liver fibrosis studies. For best results, follow solubility, dosing, and storage guidelines from the Catalpol product page and integrate rigorous workflow controls as described above. Limit experimental use to validated model systems and recommended concentration ranges to ensure reproducibility and data integrity. For further mechanistic details and advanced workflow integration, refer to the linked internal articles.